Skip to Content
 
R. Daniel  Beauchamp

R. Daniel Beauchamp, M.D., F.A.C.S.

Deputy Director, Vanderbilt-Ingram Cancer Center
Co-Leader, Gastrointestinal Cancer Research Program
John Clinton Foshee Distinguished Professor of Surgery (Surgical Oncology)
Chair, Section of Surgical Sciences
Surgeon-in-Chief, Vanderbilt University Hospital
Surgical Oncologist

  • Appointments
    615-322-2064
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Vanderbilt University Medical Center
    (615) 322-5000

    Vanderbilt Breast Center at One Hundred Oaks
    (615) 322-2064

    Office
    615-322-2363
  • Faxes
    Vanderbilt Breast Center at One Hundred Oaks Fax
    (615) 343-3343
  • Addresses
    Vanderbilt University Medical Center
    1211 Medical Center Drive
    Nashville, TN 37232
    Website

    Vanderbilt Breast Center at One Hundred Oaks
    719 Thompson Lane, Suite 25000
    Nashville, TN 37204
    Website

    Office
    Vanderbilt University Medical Center
    D-4316 Medical Center North
    Nashville, TN 37232-2729
Profile

Dr. Beauchamp is the John Clinton Foshee Distinguished Professor of Surgery, Chairman of the Section of Surgical Sciences, and Surgeon-in-Chief of Vanderbilt University Hospital and has held these positions since July 2001 and on the faculty at Vanderbilt since December 1994. His clinical practice encompassed Surgical Oncology including GI cancers, melanoma, sarcomas and breast cancer for almost 20 years, but is currently focused on breast cancer.

Dr. Beauchamp holds joint appointments as Professor in the Departments of Cell and Developmental Biology and Cancer Biology. He also serves as Deputy Director of the Vanderbilt-Ingram Cancer Center and now as co-leader of the GI Cancer Program. Dr. Beauchamp has two active R01 grants from NIH, and co-leads one of the main projects in the GI Cancer SPORE. His primary area of research interest has been in colorectal carcinogenesis, the biology of cancer cell invasion and metastasis, and in the identification of novel molecular biomarkers and therapeutic targets in colorectal and other alimentary tract malignancies. His work applies genomic, transcriptomic and proteomic technology to identify novel biomarkers and therapeutic targets in colorectal cancer. He also uses molecular genetics, chemical biology and cell biological approaches to examine mechanistic questions in cancer biology in both cell culture and mouse models. They have also developed a chemical biology project and have identified probes that inhibit Epithelial-to-Mesenchymal transition and restore E-cadherin expression in cells in which E-cadherin transcription is repressed. In addition to the basic cancer research, Dr. Beauchamp works in collaboration with his Medical Oncology and Radiation Oncology colleagues to accrue cancer patients to approved cancer clinical trials. He has trained and mentored numerous junior faculty members, physician scientist fellows, medical students, graduate students and post-doctoral fellows in his laboratory.

Education
  • M.D., The University of Texas Medical Branch, Galveston, Texas (1982)
  • B.S., Texas Tech University, Lubbock, Texas, (1978)
Research Description

R. Daniel Beauchamp, MD, is the John Clinton Foshee Distinguished Professor of Surgery, Chairman of the Section of Surgical Sciences, and Surgeon-in-Chief of Vanderbilt University Hospital and has held these positions since July 2001 and on the faculty at Vanderbilt since December 1994. He holds joint appointments as professor in the departments of Cell and Developmental Biology and Cancer Biology. He also serves as Deputy Director of the Vanderbilt-Ingram Cancer Center. Dr. Beauchamp has two active R01 grants from NIH, and leads one of the main projects in the GI Cancer SPORE. Dr. Beauchamp's primary area of research interest has been in colorectal carcinogenesis, the biology of cancer cell invasion and metastasis, and in the identification of novel molecular biomarkers and therapeutic targets in colorectal and other alimentary tract malignancies. His work applies DNA microarray and proteomic technology to identify novel biomarkers and therapeutic targets in human colorectal cancer samples. He also uses molecular genetics, chemical biology and cell biological approaches to examine mechanistic questions in cancer biology in both cell culture and mouse models. In addition to the basic cancer research Dr. Beauchamp works in collaboration with his Medical Oncology and Radiation Oncology colleagues to accrue cancer patients to approved clinical trials. He has trained and mentored numerous junior faculty members, physician scientist fellows, medical students, graduate students and post-doctoral fellows in his laboratory. He is one of the few surgeon members of the ASCI.

Publications
  • Hanson AJ, Wallace HA, Freeman TJ, Beauchamp RD, Lee LA, Lee E. XIAP monoubiquitylates Groucho/TLE to promote canonical Wnt signaling. Mol. Cell [print-electronic]. 2012 Mar 3/9/2012; 45(5): 619-28. PMID: 22304967, PMCID: PMC3299836, PII: S1097-2765(12)00042-1, DOI: 10.1016/j.molcel.2011.12.032, ISSN: 1097-4164.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22304967.
  • Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of ß-catenin. Gastroenterology [print-electronic]. 2012 Mar; 142(3): 562-571.e2. PMID: 22115830, PMCID: PMC3343368, PII: S0016-5085(11)01622-2, DOI: 10.1053/j.gastro.2011.11.026, ISSN: 1528-0012.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22115830.
  • Singh AB, Sharma A, Smith JJ, Krishnan M, Chen X, Eschrich S, Washington MK, Yeatman TJ, Beauchamp RD, Dhawan P. Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology [print-electronic]. 2011 Dec; 141(6): 2140-53. PMID: 21878201, PMCID: PMC3395068, PII: S0016-5085(11)01221-2, DOI: 10.1053/j.gastro.2011.08.038, ISSN: 1528-0012.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21878201.
  • Williams CS, Zhang B, Smith JJ, Jayagopal A, Barrett CW, Pino C, Russ P, Presley SH, Peng D, Rosenblatt DO, Haselton FR, Yang JL, Washington MK, Chen X, Eschrich S, Yeatman TJ, El-Rifai W, Beauchamp RD, Chang MS. BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. J. Clin. Invest [print-electronic]. 2011 Oct; 121(10): 4056-69. PMID: 21911938, PMCID: PMC3195453, PII: 44228, DOI: 10.1172/JCI44228, ISSN: 1558-8238.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21911938.
  • Dhawan P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK, Krishnan M, Chen X, Eschrich S, Yeatman TJ, Harris RC, Washington MK, Wilson KT, Beauchamp RD, Singh AB. Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene [print-electronic]. 2011 Jul 7/21/2011; 30(29): 3234-47. PMID: 21383692, PMCID: PMC3591522, PII: onc201143, DOI: 10.1038/onc.2011.43, ISSN: 1476-5594.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21383692.
  • Kauffmann RM, Landman MP, Shelton J, Dmochowski RR, Bledsoe SH, Hickson GB, Beauchamp RD, Dattilo JB. The use of a multidisciplinary morbidity and mortality conference to incorporate ACGME general competencies. J Surg Educ [print-electronic]. 2011 Jul; 68(4): 303-8. PMID: 21708368, PMCID: PMC3128423, PII: S1931-7204(11)00051-1, DOI: 10.1016/j.jsurg.2011.02.002, ISSN: 1878-7452.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21708368.
  • Stoops SL, Pearson AS, Weaver C, Waterson AG, Days E, Farmer C, Brady S, Weaver CD, Beauchamp RD, Lindsley CW. Identification and optimization of small molecules that restore E-cadherin expression and reduce invasion in colorectal carcinoma cells. ACS Chem. Biol [print-electronic]. 2011 May 5/20/2011; 6(5): 452-65. PMID: 21241068, PMCID: PMC3401128, DOI: 10.1021/cb100305h, ISSN: 1554-8937.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21241068.
  • Lapierre LA, Caldwell CM, Higginbotham JN, Avant KM, Hall J, Beauchamp RD, Goldenring JR. Transformation of rat intestinal epithelial cells by overexpression of Rab25 is microtubule dependent. Cytoskeleton (Hoboken) [print-electronic]. 2011 Feb; 68(2): 97-111. PMID: 21246754, PMCID: PMC3885764, DOI: 10.1002/cm.20497, ISSN: 1949-3592.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21246754.
  • Nam KT, Lee HJ, Smith JJ, Lapierre LA, Kamath VP, Chen X, Aronow BJ, Yeatman TJ, Bhartur SG, Calhoun BC, Condie B, Manley NR, Beauchamp RD, Coffey RJ, Goldenring JR. Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas. J. Clin. Invest [print-electronic]. 2010 Mar; 120(3): 840-9. PMID: 20197623, PMCID: PMC2827957, PII: 40728, DOI: 10.1172/JCI40728, ISSN: 1558-8238.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20197623.
  • Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology [print-electronic]. 2010 Mar; 138(3): 958-68. PMID: 19914252, PMCID: PMC3388775, PII: S0016-5085(09)01964-7, DOI: 10.1053/j.gastro.2009.11.005, ISSN: 1528-0012.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19914252.
  • Krishnan M, Singh AB, Smith JJ, Sharma A, Chen X, Eschrich S, Yeatman TJ, Beauchamp RD, Dhawan P. HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene [print-electronic]. 2010 Jan 1/14/2010; 29(2): 305-12. PMID: 19881542, PMCID: PMC3388773, PII: onc2009324, DOI: 10.1038/onc.2009.324, ISSN: 1476-5594.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19881542.
  • Xu BJ, Li J, Beauchamp RD, Shyr Y, Li M, Washington MK, Yeatman TJ, Whitehead RH, Coffey RJ, Caprioli RM. Identification of early intestinal neoplasia protein biomarkers using laser capture microdissection and MALDI MS. Mol. Cell Proteomics [print-electronic]. 2009 May; 8(5): 936-45. PMID: 19164278, PMCID: PMC2689774, PII: M800345-MCP200, DOI: 10.1074/mcp.M800345-MCP200, ISSN: 1535-9484.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19164278.
  • Smith JJ, Deane NG, Dhawan P, Beauchamp RD. Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology. Surgery [print-electronic]. 2008 Sep; 144(3): 353-66. PMID: 18707034, PMCID: PMC2594010, PII: S0039-6060(08)00316-4, DOI: 10.1016/j.surg.2008.05.007, ISSN: 1532-7361.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18707034.
  • Kanies CL, Smith JJ, Kis C, Schmidt C, Levy S, Khabar KS, Morrow J, Deane N, Dixon DA, Beauchamp RD. Oncogenic Ras and transforming growth factor-beta synergistically regulate AU-rich element-containing mRNAs during epithelial to mesenchymal transition. Mol. Cancer Res. 2008 Jul; 6(7): 1124-36. PMID: 18644977, PMCID: PMC2572152, PII: 6/7/1124, DOI: 10.1158/1541-7786.MCR-07-2095, ISSN: 1541-7786.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18644977.
  • Li JQ, Xu BJ, Shakhtour B, Deane N, Merchant N, Heslin MJ, Washington K, Coffey RJ, Beauchamp RD, Shyr Y, Billheimer D. Variability of in situ proteomic profiling and implications for study design in colorectal tumors. Int. J. Oncol. 2007 Jul; 31(1): 103-11. PMID: 17549410, ISSN: 1019-6439.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17549410.
  • Shiou SR, Singh AB, Moorthy K, Datta PK, Washington MK, Beauchamp RD, Dhawan P. Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells. Cancer Res. 2007 Feb 2/15/2007; 67(4): 1571-9. PMID: 17308096, PII: 67/4/1571, DOI: 10.1158/0008-5472.CAN-06-1680, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17308096.
  • Kim DW, Blanke CD, Wu H, Shyr Y, Berlin J, Beauchamp RD, Chakravarthy B. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys [print-electronic]. 2007 Feb 2/1/2007; 67(2): 397-404. PMID: 17097833, PII: S0360-3016(06)02837-9, DOI: 10.1016/j.ijrobp.2006.08.062, ISSN: 0360-3016.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17097833.
  • Shiou SR, Datta PK, Dhawan P, Law BK, Yingling JM, Dixon DA, Beauchamp RD. Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta. J. Biol. Chem [print-electronic]. 2006 Nov 11/10/2006; 281(45): 33971-81. PMID: 16959768, PII: M607010200, DOI: 10.1074/jbc.M607010200, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16959768.
  • Johnson JC, Schmidt CR, Shrubsole MJ, Billheimer DD, Joshi PR, Morrow JD, Heslin MJ, Washington MK, Ness RM, Zheng W, Schwartz DA, Coffey RJ, Beauchamp RD, Merchant NB. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin. Gastroenterol. Hepatol [print-electronic]. 2006 Nov; 4(11): 1358-65. PMID: 16996805, PII: S1542-3565(06)00772-5, DOI: 10.1016/j.cgh.2006.07.015, ISSN: 1542-3565.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16996805.
  • Halder SK, Anumanthan G, Maddula R, Mann J, Chytil A, Gonzalez AL, Washington MK, Moses HL, Beauchamp RD, Datta PK. Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis. Cancer Res. 2006 Jun 6/15/2006; 66(12): 6156-66. PMID: 16778189, PII: 66/12/6156, DOI: 10.1158/0008-5472.CAN-05-3261, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16778189.
  • Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin. Cancer Res. 2006 Mar 3/1/2006; 12(5): 1570-6. PMID: 16533783, PII: 12/5/1570, DOI: 10.1158/1078-0432.CCR-05-2304, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16533783.
  • Halder SK, Beauchamp RD, Datta PK. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp. Cell Res [print-electronic]. 2005 Jul 7/1/2005; 307(1): 231-46. PMID: 15922743, PII: S0014-4827(05)00115-1, DOI: 10.1016/j.yexcr.2005.03.009, ISSN: 0014-4827.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15922743.
  • Deane NG, Parker MA, Beauchamp RD. Cell proliferation: a matter of time and place. Surgery. 2005 Jul; 138(1): 1-7. PMID: 16003308, PII: S0039606004007287, DOI: 10.1016/j.surg.2004.12.006, ISSN: 0039-6060.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16003308.
  • Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, Neff J, Washington MK, Beauchamp RD. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J. Clin. Invest [print-electronic]. 2005 Jul; 115(7): 1765-76. PMID: 15965503, PMCID: PMC1150288, DOI: 10.1172/JCI24543, ISSN: 0021-9738.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15965503.
  • Poulose BK, Ray WA, Arbogast PG, Needleman J, Buerhaus PI, Griffin MR, Abumrad NN, Beauchamp RD, Holzman MD. Resident work hour limits and patient safety. Ann. Surg. 2005 Jun; 241(6): 847-56; discussion 856. PMID: 15912034, PMCID: PMC1357165, PII: 00000658-200506000-00002, ISSN: 0003-4932.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15912034.
  • Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005 May; 7(5): 509-21. PMID: 15967103, PMCID: PMC1501161, ISSN: 1522-8002.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15967103.
  • Tedesco KL, Berlin J, Blanke CD, Teng M, Choy H, Roberts J, Beauchamp RD, Leach S, Wyman K, Tarpley J, Shyr Y, Caillouette C, Chakravarthy B. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005 Apr 4/1/2005; 61(5): 1364-70. PMID: 15817338, PII: S0360-3016(04)02471-X, DOI: 10.1016/j.ijrobp.2004.08.050, ISSN: 0360-3016.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15817338.
  • Beauchamp RD. The changing roles of a surgical department chair: adapting to a changing environment. Arch Surg. 2005 Mar; 140(3): 258-63. PMID: 15781789, PII: 140/3/258, DOI: 10.1001/archsurg.140.3.258, ISSN: 0004-0010.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15781789.
  • Lawson LL, Sandler M, Martin W, Beauchamp RD, Kelley MC. Preoperative lymphoscintigraphy and internal mammary sentinel lymph node biopsy do not enhance the accuracy of lymphatic mapping for breast cancer. Am Surg. 2004 Dec; 70(12): 1050-5; discussion 1055. PMID: 15663043, ISSN: 0003-1348.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15663043.
  • Beauchamp RD. Department of Surgery, Vanderbilt University Medical Center, Nashville, Tenn. Arch Surg. 2004 Aug; 139(8): 814-5. PMID: 15302687, PII: 139/8/814, DOI: 10.1001/archsurg.139.8.814, ISSN: 0004-0010.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15302687.
  • Schmidt CR, Gi YJ, Coffey RJ, Beauchamp RD, Pearson AS. Oncogenic Ras dominates overexpression of E-cadherin in malignant transformation of intestinal epithelial cells. Surgery. 2004 Aug; 136(2): 303-9. PMID: 15300195, PII: S0039606004002442, DOI: 10.1016/j.surg.2004.05.004, ISSN: 0039-6060.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15300195.
  • Li JQ, Wu F, Masaki T, Kubo A, Fujita J, Dixon DA, Beauchamp RD, Ishida T, Kuriyama S, Imaida K. Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Int. J. Oncol. 2004 Jul; 25(1): 87-95. PMID: 15201993, ISSN: 1019-6439.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15201993.
  • Mithani SK, Balch GC, Shiou SR, Whitehead RH, Datta PK, Beauchamp RD. Smad3 has a critical role in TGF-beta-mediated growth inhibition and apoptosis in colonic epithelial cells. J. Surg. Res. 2004 Apr; 117(2): 296-305. PMID: 15047135, PII: S0022480403003354, DOI: 10.1016/S0022-4804(03)00335-4, ISSN: 0022-4804.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/15047135.
  • Deane NG, Lee H, Hamaamen J, Ruley A, Washington MK, LaFleur B, Thorgeirsson SS, Price R, Beauchamp RD. Enhanced tumor formation in cyclin D1 x transforming growth factor beta1 double transgenic mice with characterization by magnetic resonance imaging. Cancer Res. 2004 Feb 2/15/2004; 64(4): 1315-22. PMID: 14973059, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/14973059.
  • Parker MA, Deane NG, Thompson EA, Whitehead RH, Mithani SK, Washington MK, Datta PK, Dixon DA, Beauchamp RD. Over-expression of cyclin D1 regulates Cdk4 protein synthesis. Cell Prolif. 2003 Dec; 36(6): 347-60. PMID: 14710852, ISSN: 0960-7722.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/14710852.
  • Schmidt CR, Washington MK, Gi YJ, Coffey RJ, Beauchamp RD, Pearson AS. Dysregulation of E-cadherin by oncogenic Ras in intestinal epithelial cells is blocked by inhibiting MAP kinase. Am. J. Surg. 2003 Nov; 186(5): 426-30. PMID: 14599601, PII: S0002961003003271, ISSN: 0002-9610.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/14599601.
  • Dixon DA, Balch GC, Kedersha N, Anderson P, Zimmerman GA, Beauchamp RD, Prescott SM. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J. Exp. Med [print-electronic]. 2003 Aug 8/4/2003; 198(3): 475-81. PMID: 12885872, PMCID: PMC2194089, PII: jem.20030616, DOI: 10.1084/jem.20030616, ISSN: 0022-1007.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12885872.
  • Ahmed A, Thompson J, Emiliusen L, Murphy S, Beauchamp RD, Suzuki K, Alemany R, Harrington K, Vile RG. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat. Biotechnol [print-electronic]. 2003 Jul; 21(7): 771-7. PMID: 12794639, PII: nbt835, DOI: 10.1038/nbt835, ISSN: 1087-0156.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12794639.
  • Balch GC, Mithani SK, Richards KR, Beauchamp RD, Kelley MC. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann. Surg. Oncol. 2003 Jul; 10(6): 616-21. PMID: 12839845, ISSN: 1068-9265.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12839845.
  • Berger DH, O'Mahony CA, Sheng H, Shao J, Albo D, DuBois RN, Beauchamp RD. Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions. Surgery. 2003 May; 133(5): 568-79. PMID: 12773985, PII: S0039606003000291, DOI: 10.1067/msy.2003.125, ISSN: 0039-6060.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12773985.
  • Fujimoto K, Beauchamp RD, Whitehead RH. Identification and isolation of candidate human colonic clonogenic cells based on cell surface integrin expression. Gastroenterology. 2002 Dec; 123(6): 1941-8. PMID: 12454851, PII: S0016508502004663, DOI: 10.1053/gast.2002.37065, ISSN: 0016-5085.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12454851.
  • Berger DH, Feng XH, Yao J, Saha D, Beauchamp RD, Lin X. Resistance to transforming growth factor-beta occurs in the presence of normal Smad activation. Surgery. 2002 Aug; 132(2): 310-6. PMID: 12219028, PII: S0039606002000892, ISSN: 0039-6060.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12219028.
  • Saha D, Roman C, Beauchamp RD. New strategies for colorectal cancer prevention and treatment. World J Surg [print-electronic]. 2002 Jul; 26(7): 762-6. PMID: 11948369, DOI: 10.1007/s00268-002-4049-1, ISSN: 0364-2313.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11948369.
  • Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, Beauchamp RD. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J. Surg. Res. 2002 Jun 6/1/2002; 105(1): 43-7. PMID: 12069500, PII: S0022480402964449, DOI: 10.1006/jsre.2002.6444, ISSN: 0022-4804.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12069500.
  • Roman CD, Morrow J, Whitehead R, Beauchamp RD. Induction of cyclooxygenase-2 and invasiveness by transforming growth factor-beta(1) in immortalized mouse colonocytes expressing oncogenic Ras. J. Gastrointest. Surg. 2002 May; 6(3): 304-9. PMID: 12022979, PII: S1091255X01000415, ISSN: 1091-255X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/12022979.
  • Roman CD, Hanley GA, Beauchamp RD. Operative technique for safe pulmonary lobectomy in Sprague-Dawley rats. Contemp Top Lab Anim Sci. 2002 Mar; 41(2): 28-30. PMID: 11958600, ISSN: 1060-0558.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11958600.
  • Saha D, Datta PK, Beauchamp RD. Oncogenic ras represses transforming growth factor-beta /Smad signaling by degrading tumor suppressor Smad4. J. Biol. Chem [print-electronic]. 2001 Aug 8/3/2001; 276(31): 29531-7. PMID: 11371552, PII: M100069200, DOI: 10.1074/jbc.M100069200, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11371552.
  • Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, Nanney LB, Shyr Y, Beauchamp RD. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res. 2001 Jul 7/15/2001; 61(14): 5389-95. PMID: 11454681, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11454681.
  • Fujimoto K, Sheng H, Shao J, Beauchamp RD. Transforming growth factor-beta1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells. Exp. Cell Res. 2001 Jun 6/10/2001; 266(2): 239-49. PMID: 11399052, PII: S0014-4827(00)95229-7, DOI: 10.1006/excr.2000.5229, ISSN: 0014-4827.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11399052.
  • Zhang Z, Sheng H, Shao J, Beauchamp RD, DuBois RN. Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia. 2000 Nov; 2(6): 523-30. PMID: 11228545, PMCID: PMC1508084, ISSN: 1522-8002.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11228545.
  • Fujimoto K, Hosotani R, Miyamoto Y, Doi R, Koshiba T, Otaka A, Fujii N, Beauchamp RD, Imamura M. Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16(INK4A) fusion peptide in pancreatic cancer cells. Cancer Lett. 2000 Oct 10/31/2000; 159(2): 151-8. PMID: 10996726, PII: S030438350000536X, ISSN: 0304-3835.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10996726.
  • Beauchamp RD. Presidential address: evolution. Surgery. 2000 Aug; 128(2): 123-32. PMID: 10922981, PII: S0039-6060(00)06170-5, DOI: 10.1067/msy.2000.108057, ISSN: 0039-6060.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10922981.
  • Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J. Biol. Chem. 2000 Jul 7/28/2000; 275(30): 22916-24. PMID: 10781597, PII: M002235200, DOI: 10.1074/jbc.M002235200, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10781597.
  • Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem. 2000 Mar 3/3/2000; 275(9): 6628-35. PMID: 10692471, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10692471.
  • Jo H, Zhang R, Zhang H, McKinsey TA, Shao J, Beauchamp RD, Ballard DW, Liang P. NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene. 2000 Feb 2/17/2000; 19(7): 841-9. PMID: 10702792, DOI: 10.1038/sj.onc.1203392, ISSN: 0950-9232.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10702792.
  • Bulus N., Sheng H-M., Sizemore N., Oldham S.M., Barnett J.V., Coffey R.J., Beauchamp R.D. and Barnard J.A. Ras-mediated suppression of TFGRII expression in intestinal pedithelial cells involves a Raf-independent signaling. Neoplasia. 2000; 2((4)): 357-64.
  • Shao, J., Sheng, H.M., Dubois, R.N., and Beauchamp, R.D. Oncogenic Ras-mediated cell growth arrest and apoptosis is associated with increased ubiquitin-dependent cyclin D1 degradation. Journal of Biological Chemistry. 2000; 275: 22916-24.
  • Sheng, H., Shao, J., Williams, C.S., Prescott, S.M., Dubois, R.N., and Beauchamp, R.D. TGF-1 enhances Ha-Ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. Journal of Biological Chemistry. 2000; 275: 6628-35.
  • Saha D, Datta PK, Sheng H, Morrow JD, Wada M, Moses HL, Beauchamp RD. Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia. 1999 Dec; 1(6): 508-17. PMID: 10935498, PMCID: PMC1508120, ISSN: 1522-8002.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10935498.
  • Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J. Nucl. Med. 1999 Nov; 40(11): 1784-91. PMID: 10565771, ISSN: 0161-5505.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10565771.
  • Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann. Surg. Oncol. 1999 Oct; 6(7): 651-7. PMID: 10560850, ISSN: 1068-9265.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10560850.
  • Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann. Surg. 1999 May; 229(5): 729-37; discussion 737. PMID: 10235532, PMCID: PMC1420818, ISSN: 0003-4932.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10235532.
  • Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, Grogan L, Kirsch IR, Washington MK, Beauchamp RD, DuBois RN. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis. 1999 Feb; 20(2): 185-91. PMID: 10069452, ISSN: 0143-3334.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10069452.
  • Sheng H, Shao J, O'Mahony CA, Lamps L, Albo D, Isakson PC, Berger DH, DuBois RN, Beauchamp RD. Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Oncogene. 1999 Jan 1/28/1999; 18(4): 855-67. PMID: 10023661, DOI: 10.1038/sj.onc.1202397, ISSN: 0950-9232.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/10023661.
  • Shao, J., Sheng, H.M., Aramandla, R., Pereira, M.A., Lubet, R.A., Hawk, E., Grogan, L., Kirshc, I.R., Washington, M.K., Beauchamp, R.D. and Dubois, R.N. Coordinate regulation of cyclooxygenase-2 and TGF-1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis. 1999; 20((2)): 185-91.
  • Sheng, H., Shao, J., O'Mahony, C.A., Lamps, L., Albo, D., Isakson, P.C., Berger, D.H., DuBois, R.N., and Beauchamp, R.D. Transformation of intestinal epithelial cells by chronic TGF-b1 treatment results in downregulation of the type II TGF-b receptor and induction of cyclooxygenase-2. Oncogene. 1999; 18: 855-67.
  • Sheng H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J. Biol. Chem. 1998 Aug 8/21/1998; 273(34): 22120-7. PMID: 9705357, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9705357.
  • Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffey RJ, Morrow JD. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. Cancer Res. 1998 Jun 6/1/1998; 58(11): 2323-7. PMID: 9622066, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9622066.
  • Sheng H, Shao J, Williams CS, Pereira MA, Taketo MM, Oshima M, Reynolds AB, Washington MK, DuBois RN, Beauchamp RD. Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas. Carcinogenesis. 1998 Apr; 19(4): 543-9. PMID: 9600336, ISSN: 0143-3334.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9600336.
  • Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998 Jan 1/15/1998; 58(2): 362-6. PMID: 9443418, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9443418.
  • Chinery, R., Beauchamp, R.D., Shyr, Y., Kirkland, S.C., Coffey, R.J., and Morrow, J.D. Antioxidants reduce cyclooxygenase -2 expression, prostaglandin production and proliferation in colorectal cancer cells. Cancer Research. 1998; 58: 2323-7.
  • Ko, T.C., Yu, W., Sakai, T., Sheng, H., Shao, J., Beauchamp, R.D and Thompson, E.A. TGF-b1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression. Oncogene. 1998; 16: 3445-54.
  • Sheng, H., Shao, J., Morrow, J., Beauchamp, R., DuBois, R. Modulation of Apoptosis and Bcl-2 Expression by Prostaglandin E2 in Human Colon Cancer Cells. Cancer Research. 1998; 58: 362-6.
  • Sheng, H., Shao,J., Williams, C.S., Pereira, M.A., Taketo, M.M., Oshima, M., Reynolds, A.B., Washington, M.W., DuBois, R.N and Beauchamp, R.D. Nuclear translocation of b-catenin in hereditary and carcinogen- induced intestinal adenomas. Carcinogenesis. 1998; 19: 543-9.
  • Sheng, H., Williams, C.S., Shao, J., Liang, P., DuBois, R.N., and Beauchamp, R.D. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. Journal of Biological Chemistry. 1998; 22120-7.
  • Washington, K., Chiappori, A., Hamilton, K., Yu, S., Blanke, C., johnson, D., Sawyers, J., and Beauchamp, R.D. Expression of -catenin, -catenin, and E-cadherin in Barrett?s esophagus and esophageal adenocarcinomas. Modern Pathology. 1998; 11((9)): 805-13.
  • Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, Coffey RJ, DuBois RN, Beauchamp RD. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology. 1997 Dec; 113(6): 1883-91. PMID: 9394727, PII: S0016508597005556, ISSN: 0016-5085.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9394727.
  • Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat. Med. 1997 Nov; 3(11): 1233-41. PMID: 9359698, ISSN: 1078-8956.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9359698.
  • Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 1997 May 5/1/1997; 99(9): 2254-9. PMID: 9151799, PMCID: PMC508057, DOI: 10.1172/JCI119400, ISSN: 0021-9738.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9151799.
  • Zhang T, Nanney LB, Peeler MO, Williams CS, Lamps L, Heppner KJ, DuBois RN, Beauchamp RD. Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Res. 1997 May 5/1/1997; 57(9): 1638-43. PMID: 9134999, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9134999.
  • Sheng H, Shao J, Hooton EB, Tsujii M, DuBois RN, Beauchamp RD. Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. Cell Growth Differ. 1997 Apr; 8(4): 463-70. PMID: 9101092, ISSN: 1044-9523.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/9101092.
  • Zhang T, Nanney LB, Luongo C, Lamps L, Heppner KJ, DuBois RN, Beauchamp RD. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res. 1997 Jan 1/1/1997; 57(1): 169-75. PMID: 8988060, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8988060.
  • Chinery, R., Brockman, J.A., Peeler, M.O., Shyr, Y., Beauchamp, R.D., and Coffey, R.J. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21Waf1/Cip1 via C/EBP. Nature Medicine. 1997; 3: 1-9.
  • Sheng, G., Shao, J., Sheng, H., Hooton, E., Isakson, P., Morrow, J., Coffey, R., DuBois, R., Beauchamp, R. A Selective Cyclooxygenase 2 Inhibitor Suppresses the Growth of H-ras-Transformed Rat Intestinal Epithelial Cells. Gastroenterology. 1997; 113: 1883-91.
  • Sheng, H., Shao, J., Hooton, E.B., Masahiko, T., DuBois, R.N., Beauchamp, R.D. Cyclooxygenase-2 induction and transforming growth factor (TGF)-b growth inhibition in rat intestinal epithelial cells. Cell Growth and Differentiation. 1997; 8: 463-70.
  • Sheng, H., Shao, J., Kirkland, S.C., Isakson, P., Coffey, R.J., Morrow, J., Beauchamp, R.D., DuBois R.N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. The Journal of Clinical Investigation. 1997; 99: 2254-9.
  • Zhang, T., Nanney, L.B., Luongo, C., Lamps, L., Heppner, K.J., DuBois, R.N., and Beauchamp, R.D. Concurrent overexpression of cyclin D1 and Cdk4 in intestinal adenomas from min mice and human familial adenomatous polyposis patients. Cancer Research. 1997; 57: 169-75.
  • Zhang, T., Nanney, L.B., Peeler, M.O., Williams, C.S., Lamps, L., Heppner, K.J., DuBois, R.N., and Beauchamp, R.D. Decreased TFG- type II receptor expression in intestinal adenomas from Min/+ Mice is associated with increased cyclin D1 and Cdk4 expression. Cancer Research. 1997; 57: 1638-43.
  • Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, Beauchamp RD, DuBois RN. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. 1996 Oct; 111(4): 1134-40. PMID: 8831610, PII: S0016-5085(96)70083-5, ISSN: 0016-5085.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8831610.
  • Beauchamp RD, Sheng HM, Shao JY, Thompson EA, Ko TC. Intestinal cell cycle regulations. Interactions of cyclin D1, Cdk4, and p21Cip1. Ann. Surg. 1996 May; 223(5): 620-7; discussion 627. PMID: 8651753, PMCID: PMC1235195, ISSN: 0003-4932.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8651753.
  • DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 1996 Feb 2/15/1996; 56(4): 733-7. PMID: 8631005, ISSN: 0008-5472.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/8631005.
  • DuBois, R. N., Shao, J., Masahiko, T., Sheng, H-M., Beauchamp, R.D. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-21. Cancer Research. 1996; 56: 733-7.
  • Williams, C.S., Luongo, C., Radhika, A., Zhang, R., Lamps, L.W., Nanney, L.B., Beauchamp, R.D., Dubois, R.N. Elevated cyclooxygenase-2 levels in min mouse adenomas. Gastroenterology. 1996; 111: 1134-40.
  • Barnard JA, Beauchamp RD, Russell WE, Dubois RN, Coffey RJ. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology. 1995 Feb; 108(2): 564-80. PMID: 7835600, ISSN: 0016-5085.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/7835600.
  • Barnard, J.A., Beauchamp, R.D., Russell, W.E., DuBois, R.N., Coffey, R.J. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology. 1995; 108: 564-80.
  • Ko, T.C., Sheng, H.M.,,Reisman, D., Thompson, E.A., Beauchamp, R.D. Transforming growth factor- inhibits cyclin D1 Expression of intestinal epithelial clls. Oncongene. 1995; 10: 177-84.
  • Beauchamp, R.D., Papaconstantinou, J., Henderson, A.M., Sheng, H-M., Townsend, C.M. Jr.,Thompson, J.C. Activation of hepatic proliferation-associated transcription factors by lipopolysaccharide. Surgery. 1994; 116: 367-77.
  • Ko, T.C., Beauchamp, R.D., Townsend, C.M. Jr., Thompson, E.A., Thompson, J.C. Transforming growth factor beta inhibits rat intestinal cell growth by regulating cell cycle specific gene expression. American Journal of Surgery. 1994; 167: 14-20.
  • Parekh, D., Ishizuka, J., Townsend, C.M. Jr., Haber, B., Beauchamp, R.D., Karp, G., Kim, S.W., Rajaraman, S., Greeley, G.H. Jr., Thompson, J.C. Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage and secretion. Pancreas. 1994; 9: 83-90.
  • Sumi, S., Beauchamp, R.D., Townsend, C.M. Jr., Pour, P.M., Ishizuka, J., Thompson, J.C. Lovastatin inhibits pancreatic cancer growth regardless of ras mutation. Pancreas. 1994; 90: 657-61.
  • Guo, Y-S., Beauchamp, RD., Jin, G-F., Townsend, C.M. Jr., Thompson, J.C. Insulinlike growth factor-binding protein modulates the growth response to insulinlike growth factor 1 by human gastric cancer cells. Gastroenterology. 1993; 104: 1595-604.
  • Ishizuka, J., Beauchamp, R.D., Sato, K., Townsend, C.M. Jr., Thompson, J.C. Novel action of transforming growth factor  1 in functioning human pancreatic carcinoid cells. Journal of Cellular Physiology. 1993; 156: 112-8.
  • Ko, T.C., Beauchamp, R.D., Townsend, C.M. Jr., Thompson, J.C. Glutamine is essential for epidermal growth factor-stimulated intestinal cell proliferation. Surgery. 1993; 114: 147-54.
  • Polk WH, Dempsey PJ, Russell WE, Brown PI, Beauchamp RD, Barnard JA, Coffey RJ. Increased production of transforming growth factor alpha following acute gastric injury. Gastroenterology. 1992 May; 102(5): 1467-74. PMID: 1568557, PII: S0016508592001859, ISSN: 0016-5085.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/1568557.
  • Beauchamp, R.D., Sheng, H-M., Alam, T., Townsend, C.M. Jr., Papaconstantinou, J. Posttranscriptional regulation of albumin and -fetoprotein messenger RNA by transforming growth factor- 1 requires de novo RNA and protein synthesis. Molecular Endocrinology. 1992; 6: 1789-96.
  • Beauchamp, R.D., Sheng, H-M., Ishizuka, J., Townsend, C.M. Jr., Thompson, J.C. Transforming growth factor (TGF)- stimulates hepatic jun-B and fos-B proto-oncogenes and decreases albumin mRNA. Annals of Surgery. 1992; 216: 300-8.
  • Chung, D.H., Evers, B.M., Beauchamp, R.D., Upp, J.R. Jr., Rajaraman, S., Townsend, C.M. Jr., Thompson, J.C. Bombesin stimulates growth of human gastrinoma. Surgery. 1992; 112: 1059-65.
  • Ishizuka, J., Beauchamp, R.D., Evers, B.M., Townsend, C.M. Jr., Thompson, J.C. Unexpected growth-stimulatory effect of somatostatin analogue on cultured human pancreatic carcinoid cells. Biochemical and Biophysical Research Communications. 1992; 185: 577-81.
  • Sumi, S., Beauchamp, R.D., Townsend, C.M. Jr., Uchida, T., Murakami, M., Rajaraman, S., Ishizuka, J., Thompson, J.C. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology. 1992; 103: 982-9.
  • Beauchamp RD, Lyons RM, Yang EY, Coffey RJ, Moses HL. Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines. Pancreas. 1990 Jul; 5(4): 369-80. PMID: 2199964, ISSN: 0885-3177.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2199964.
  • Beauchamp RD, Barnard JA, McCutchen CM, Cherner JA, Coffey RJ. Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal. J. Clin. Invest. 1989 Sep; 84(3): 1017-23. PMID: 2760208, PMCID: PMC329750, DOI: 10.1172/JCI114223, ISSN: 0021-9738.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2760208.
  • Barnard JA, Beauchamp RD, Coffey RJ, Moses HL. Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc. Natl. Acad. Sci. U.S.A. 1989 Mar; 86(5): 1578-82. PMID: 2466294, PMCID: PMC286741, ISSN: 0027-8424.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/2466294.